Media coverage about Xencor (NASDAQ:XNCR) has been trending somewhat positive this week, according to Accern. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Xencor earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.4306373341261 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the headlines that may have effected Accern’s rankings:

Xencor (NASDAQ XNCR) opened at 21.73 on Monday. The stock’s 50 day moving average price is $21.61 and its 200 day moving average price is $22.66. The firm’s market capitalization is $1.02 billion. Xencor has a 12 month low of $18.45 and a 12 month high of $29.38.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.10. The company had revenue of $13.34 million during the quarter, compared to analyst estimates of $8.15 million. Xencor had a negative net margin of 121.04% and a negative return on equity of 13.79%. On average, analysts forecast that Xencor will post ($1.17) earnings per share for the current year.

A number of equities analysts have commented on the company. Canaccord Genuity restated a “buy” rating and issued a $36.00 target price on shares of Xencor in a research note on Tuesday, August 8th. ValuEngine upgraded Xencor from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. BidaskClub downgraded Xencor from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Zacks Investment Research downgraded Xencor from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Finally, Wedbush restated an “outperform” rating and issued a $29.00 target price on shares of Xencor in a research note on Friday, June 16th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $29.33.

TRADEMARK VIOLATION NOTICE: This article was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/09/18/xencor-xncr-earning-somewhat-positive-news-coverage-study-finds.html.

In other news, major shareholder John S. Stafford III acquired 6,000 shares of the company’s stock in a transaction dated Wednesday, June 28th. The stock was bought at an average price of $19.94 per share, with a total value of $119,640.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder John S. Stafford III acquired 79,035 shares of the company’s stock in a transaction dated Thursday, August 17th. The shares were purchased at an average cost of $20.47 per share, with a total value of $1,617,846.45. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 221,551 shares of company stock valued at $4,506,556. Company insiders own 4.03% of the company’s stock.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Insider Buying and Selling by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.